THE GENERAL HOSPITAL CORPORATION;GENZYME CORPORATION
发明人:
James B. Streisand,Jesse D. Roberts, JR.
申请号：
US15362392
公开号：
US20170233464A1
申请日:
2016.11.28
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-β antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-β antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
